---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010933"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T12:45:54.357872+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Director Celeste Fralick resigns from Aspira Women's Health board

## Summary
- Celeste Fralick resigned as director for personal reasons, effective March 31, 2025.
- No replacement has been announced; board size will decrease by one.
- Resignation communicated on March 15, 2025; filing made March 19, 2025.

## SEC filing metadata
- accession: 0001493152-25-010933
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000149315225010933/0001493152-25-010933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000149315225010933/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010933
- JSON: https://secwatch.observer/filing/0001493152-25-010933.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010933.txt

## Key facts
- Executive change
  Celeste Fralick resigned as director at Aspira Women's Health Inc..
  - Action: resigned
  - Role: director
  source text: On March 15, 2025, Celeste Fralick informed the Board of Directors of Aspira Women’s Health Inc. (the “Company”) that she was resigning as a director of the Company, for personal reasons, effective March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000149315225010933/0001493152-25-010933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.